News Focus
News Focus
Followers 59
Posts 7590
Boards Moderated 0
Alias Born 10/20/2014

Re: Markipeach post# 227024

Friday, 11/15/2019 6:47:21 PM

Friday, November 15, 2019 6:47:21 PM

Post# of 447448
Markipeach, Of course I always viewed AMRN as being a logical takeover
candidate in the evolution of Vascepa's development as a Cardiovascular
drug. If BP believes in Vascepa the way posters here in the GIA camp
believe in Vascepa's potential...well, it would be all over.

The market needs a generic settlement, which is most likely prior
to the scheduled trial date of Jan. 13. Before the end of December
the FDA should give us their label for the CVD indication. With
these two events the "takeover window" will be open. Whether or
not AMRN announces a partner for Europe may tell us the answer.
As long as no partner is announced it is then possible AMRN is
holding out for a takeout. If a partner is announced a takeover
is far less likely.

Given the multi-year record share price today I think investors are
buying because they believe a takeover is likely in the near term.
What I think does not matter. I am of the opinion that JT has his
"price" where he will take an offer to the BOD. My belief is that
Vascepa in the hands of BP will get Vascepa into the hands of patients
much faster and more broadly than AMRN by itself. That is how the
process works...like it or not.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News